BiotechTube

IV Remodulin + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Persistent Pulmonary Hypertension of the Newborn

Conditions

Persistent Pulmonary Hypertension of the Newborn

Trial Timeline

Jul 29, 2015 → May 17, 2023

NCT ID
NCT02261883

About IV Remodulin + Placebo

IV Remodulin + Placebo is a phase 2 stage product being developed by United Therapeutics for Persistent Pulmonary Hypertension of the Newborn. The current trial status is terminated. This product is registered under clinical trial identifier NCT02261883. Target conditions include Persistent Pulmonary Hypertension of the Newborn.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02261883Phase 2Terminated

Competing Products

20 competing products in Persistent Pulmonary Hypertension of the Newborn

See all competitors
ProductCompanyStageHype Score
E7777 9 mcg/kgEisaiPhase 3
77
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment EAstraZenecaPhase 1
33
AZD0837 + VKA INR 2-3AstraZenecaPhase 2
52
AZD0837 + AspirinAstraZenecaPhase 2
52
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
23
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone AcetateNovartisPhase 2
52
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
85
CertoparinNovartisPhase 3
77
Omalizumab + PlaceboNovartisPhase 3
77
RivastigmineNovartisApproved
85
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 daysNovartisPhase 2
52
Indacaterol + Placebo to IndacaterolNovartisPhase 2
52
Omalizumab + PlaceboNovartisApproved
85
placebo + iv sildenafilPfizerPhase 3
76
etanercept + placeboPfizerPhase 2
51
SildenafilPfizerPhase 2
51
irbesartan + placeboSanofiApproved
84
iloprostBayerPre-clinical
20
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)GlaukosPhase 2
49

Other Products from United Therapeutics

TreprostinilApproved
82
RemodulinApproved
82
Remodulin (treprostinil sodium)Approved
82
Intravenous TreprostinilApproved
82
Intravenous/Subcutaneous Treprostinil; Oral TreprostinilApproved
82